← All trials
NCT07281079
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 12, 2025
- Primary completion
- Oct 31, 2027
- Completion date
- Nov 15, 2027
- First posted
- Dec 15, 2025
- Last posted
- Dec 15, 2025
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neuren Pharmaceuticals LimitedLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.